Financial Data and Key Metrics Changes - Bruker's Q3 2025 reported revenues decreased 0.5% to $860.5 million, with an organic revenue decline of 4.5% [10][20] - Non-GAAP operating margin for Q3 2025 was 12.3%, down 260 basis points year over year, but improved sequentially from 9.0% in Q2 2025 [10][22] - Diluted non-GAAP EPS for Q3 2025 was $0.45, down 25% from $0.60 in Q3 2024, but up sequentially from $0.32 in Q2 2025 [10][22] Business Line Data and Key Metrics Changes - Scientific instruments organic revenue segment declined 5.4% in Q3 2025, with a mid-single digit organic growth in Kallid offset by declines in Biospin and Bruker Nano [20] - Year-to-date 2025 revenue for the Biospin Group was $612 million, down mid-single digits, while CALID Group revenue increased in the low double-digit percentage [11][12] - Bruker Nano revenue for year-to-date 2025 was $775 million, declining in the low single-digit percentage [12] Market Data and Key Metrics Changes - Organic scientific instruments orders in China increased by double-digit percentage in Q3 2025, indicating potential stimulus funding [8] - Americas revenue declined in the low single-digit percentage, while European revenue was roughly flat, and Asia-Pacific revenue declined in the mid-single-digit percentage [20] - IMEA region revenue declined by over 20% [20] Company Strategy and Development Direction - The company is focusing on significant cost savings initiatives, targeting $100 million-$120 million for 2026, which is expected to drive margin expansion and double-digit EPS growth [9][17] - Bruker is emphasizing its transformed project Accelerate 2.0 portfolio, which includes opportunities in post-genomic drug discovery, innovative diagnostics, and automated AI labs [18][19] - The company aims to outgrow its markets by 200-300 basis points per year on average by 2027, despite current headwinds [19] Management's Comments on Operating Environment and Future Outlook - Management noted that Q3 2025 performance was better than expected, with improved bookings and a book-to-bill ratio above 1.0, suggesting a potential recovery in demand [5][17] - The company expects significant improvements in organic revenue performance in 2026 compared to the decline in 2025 [17][26] - Management remains cautious about the impact of the government shutdown on Q4 and its potential effects on orders and installations [32] Other Important Information - The company reported a GAAP diluted loss per share of $0.41 due to non-cash goodwill and intangibles impairment charges of $119.4 million [22] - The updated full-year 2025 revenue forecast is now in the range of $3.41 billion-$3.44 billion, reflecting an organic revenue decline of 4%-5% [24] Q&A Session Summary Question: How has the order momentum trended in Q4? - Management indicated it is too early to comment on Q4 order trends as no meaningful data is available yet [27][28] Question: What is the impact of the government shutdown on the outlook? - The effect of the government shutdown is not formally baked into the outlook, but it could delay new grants and installations if it continues [32] Question: Can the company grow revenues in 2026? - Management refrained from making assumptions about revenue growth for 2026, emphasizing the need to see Q4 bookings first [34][36] Question: What is the outlook for diagnostics and semiconductors in 2026? - Diagnostics are expected to continue performing well, while semiconductor revenue is anticipated to improve next year [48][50]

Financial Data and Key Metrics Changes - Bruker's reported revenues for Q2 2025 decreased by 0.4% year over year to $797.4 million, with an organic revenue decline of 7% [16][26][27] - Non-GAAP diluted EPS was $0.32, down 39% from $0.52 in 2024, primarily due to organic revenue decline, tariff impacts, and foreign exchange headwinds [18][29] - Non-GAAP operating margin was 9%, a decrease of 480 basis points year over year, impacted by lower revenue absorption and additional costs [18][28] Business Line Data and Key Metrics Changes - The Scientific Instruments (BSI) segment experienced a 7.2% organic revenue decline, with BSI Systems declining roughly 10% [27][28] - The CALID Group revenue increased in the low teens percentage, driven by strong growth in microbiology and infection diagnostics [20] - BEST revenues declined in the low teens percentage due to softness in the clinical MRI market [21] Market Data and Key Metrics Changes - Americas revenue declined in the low double digits percentage, while European revenue also saw a similar decline [27] - Asia Pacific revenue grew in the low single digits percentage, despite a low single-digit decline in China [27] - EMEA region revenue was up in the high single digits percentage [27] Company Strategy and Development Direction - The company is expanding cost-saving initiatives, aiming to reduce annual costs by €100 million to €120 million, affecting all business areas [14][31] - Bruker is focused on reaccelerating growth in the post-genomic era, particularly in biopharma drug discovery tools [12][24] - The company anticipates a return to organic revenue growth of 200 to 300 basis points above market levels beyond 2026 [15] Management's Comments on Operating Environment and Future Outlook - Management noted that the life science research instruments market is under pressure due to U.S. academic funding headwinds and delays in China stimulus [8][9] - The company expects a flat constant exchange rate revenue growth and an organic revenue decline of 2% to 4% for fiscal year 2025 [15][32] - Management remains cautiously optimistic about a partial recovery in fiscal year 2026, driven by significant margin improvements and cost reduction initiatives [35] Other Important Information - The company is observing tariff settlements and anticipates that global biopharma and industrial companies will accelerate investments once uncertainties are resolved [11][12] - Bruker is leveraging its backlog, which has slightly decreased from seven months to 6.5 months, to manage revenue expectations [39][98] Q&A Session Summary Question: Why is the backlog not helping this year? - Management indicated that while the backlog is being utilized, production and delivery times are planned and locked in by customers, leading to a slight decrease in backlog duration from seven months to 6.5 months [39] Question: What is the expectation for ultra-high field revenue recognition? - Management does not expect ultra-high field revenue recognition in Q3 but anticipates it in Q4 [43] Question: Why were cost-saving initiatives not initiated sooner? - Management explained that initial savings programs were started earlier in the year, but the expansion of cost-saving measures was necessary due to emerging headwinds [48][50] Question: What is the outlook for fiscal year 2026? - Management expressed uncertainty about growth in 2026 but emphasized the commitment to significant margin expansion and EPS growth regardless of market conditions [51][56] Question: How is the company addressing the free cash flow burn in Q2? - Management noted unusual outflows related to tax payments, which are not expected to recur, and anticipates a return to normal cash flow levels [65][66] Question: What is the visibility into the Q4 ramp? - Management acknowledged that Q4 typically sees a significant ramp, but visibility remains challenging due to current market conditions [101]